Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Net Margin for 10 consecutive years, with 59.13% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 31956.0% to 59.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 84.55% through Dec 2025, down 8330.0% year-over-year, with the annual reading at 84.55% for FY2025, 8330.0% down from the prior year.
  • Net Margin for Q4 2025 was 59.13% at Ultragenyx Pharmaceutical, up from 112.81% in the prior quarter.
  • The five-year high for Net Margin was 381.81% in Q4 2023, with the low at 270.23% in Q3 2022.
  • Average Net Margin over 5 years is 91.38%, with a median of 138.87% recorded in 2021.
  • The sharpest move saw Net Margin skyrocketed 53195bps in 2023, then tumbled -31956bps in 2025.
  • Over 5 years, Net Margin stood at 149.65% in 2021, then fell by 0bps to 150.13% in 2022, then skyrocketed by 354bps to 381.81% in 2023, then plummeted by -32bps to 260.43% in 2024, then crashed by -123bps to 59.13% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 59.13%, 112.81%, and 69.04% for Q4 2025, Q3 2025, and Q2 2025 respectively.